Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress

RefinitivLess than 1 min read

Alnylam Pharmaceuticals Inc ALNY:

ALNYLAM TO SHARE PROGRESS ACROSS ITS TRANSTHYRETIN AMYLOIDOSIS FRANCHISE INCLUDING ADDITIONAL ANALYSES OF THE HELIOS-B PHASE 3 STUDY RESULTS AT HEART FAILURE 2025 CONGRESS

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Login or create a forever free account to read this news